tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PRXL

AstraZeneca’s AZD4144 Study Completion: Key Insights for Investors
Company AnnouncementsAstraZeneca’s AZD4144 Study Completion: Key Insights for Investors
16h ago
AZN
PRXL
AstraZeneca’s New Trial: A Potential Game-Changer in Prostate Cancer Treatment
PremiumCompany Announcements
AstraZeneca’s New Trial: A Potential Game-Changer in Prostate Cancer Treatment
16h ago
AZN
PRXL
AstraZeneca’s ASTER Study: Real-World Insights into Anifrolumab for SLE
PremiumCompany Announcements
AstraZeneca’s ASTER Study: Real-World Insights into Anifrolumab for SLE
17h ago
AZN
PRXL
AstraZeneca’s Latest Study: Evaluating Ceralasertib’s Impact on Cancer Drug Pharmacokinetics
PremiumCompany Announcements
AstraZeneca’s Latest Study: Evaluating Ceralasertib’s Impact on Cancer Drug Pharmacokinetics
17h ago
AZN
PRXL
AstraZeneca’s Latest Study on AZD2389 and Quinidine: Key Insights for Investors
PremiumCompany Announcements
AstraZeneca’s Latest Study on AZD2389 and Quinidine: Key Insights for Investors
17h ago
AZN
PRXL
AstraZeneca’s Tezepelumab Study: A Potential Game-Changer in Severe Asthma Treatment
PremiumCompany AnnouncementsAstraZeneca’s Tezepelumab Study: A Potential Game-Changer in Severe Asthma Treatment
2d ago
AZN
PRXL
AstraZeneca Completes Key Study on AZD2389’s Drug Interaction Effects
Premium
Company Announcements
AstraZeneca Completes Key Study on AZD2389’s Drug Interaction Effects
2d ago
AZN
PRXL
AstraZeneca’s Phase III Study on Anifrolumab for Cutaneous Lupus: Key Insights for Investors
Premium
Company Announcements
AstraZeneca’s Phase III Study on Anifrolumab for Cutaneous Lupus: Key Insights for Investors
2d ago
AZN
PRXL
AstraZeneca’s ASTER Study: Real-World Insights into Anifrolumab for SLE
PremiumCompany Announcements
AstraZeneca’s ASTER Study: Real-World Insights into Anifrolumab for SLE
3d ago
AZN
PRXL
AstraZeneca’s AZD4144 Study Completion: Market Implications and Insights
PremiumCompany Announcements
AstraZeneca’s AZD4144 Study Completion: Market Implications and Insights
3d ago
AZN
PRXL
AstraZeneca’s New Prostate Cancer Study: A Potential Game Changer?
PremiumCompany Announcements
AstraZeneca’s New Prostate Cancer Study: A Potential Game Changer?
3d ago
AZN
PRXL
AstraZeneca’s Phase 4 Study on Tezepelumab: A Boost for Severe Asthma Treatment
PremiumCompany Announcements
AstraZeneca’s Phase 4 Study on Tezepelumab: A Boost for Severe Asthma Treatment
4d ago
AZN
PRXL
AstraZeneca’s Phase I Study on AZD6234: A Potential Game-Changer in Obesity Treatment
PremiumCompany AnnouncementsAstraZeneca’s Phase I Study on AZD6234: A Potential Game-Changer in Obesity Treatment
8d ago
AZN
PRXL
AstraZeneca’s Phase III Study on Benralizumab: A Potential Game-Changer for Pediatric Asthma
Premium
Company Announcements
AstraZeneca’s Phase III Study on Benralizumab: A Potential Game-Changer for Pediatric Asthma
9d ago
AZN
PRXL
AstraZeneca’s New Obesity Drug: A Potential Game-Changer?
Premium
Company Announcements
AstraZeneca’s New Obesity Drug: A Potential Game-Changer?
10d ago
AZN
PRXL
AstraZeneca’s NeoCOAST-2 Study: A New Horizon in Lung Cancer Treatment
PremiumCompany Announcements
AstraZeneca’s NeoCOAST-2 Study: A New Horizon in Lung Cancer Treatment
12d ago
AZN
PRXL
AstraZeneca’s New Study on Saruparib: A Potential Game-Changer in Prostate Cancer Treatment
PremiumCompany Announcements
AstraZeneca’s New Study on Saruparib: A Potential Game-Changer in Prostate Cancer Treatment
15d ago
AZN
PRXL
AstraZeneca’s Latest Study on AZD4248: A Potential Game-Changer in Diabetes and Kidney Disease Treatment
PremiumCompany Announcements
AstraZeneca’s Latest Study on AZD4248: A Potential Game-Changer in Diabetes and Kidney Disease Treatment
15d ago
AZN
PRXL
AstraZeneca’s Asthma Study: A Potential Game-Changer for Adolescent Treatment
PremiumCompany Announcements
AstraZeneca’s Asthma Study: A Potential Game-Changer for Adolescent Treatment
15d ago
AZN
PRXL
AstraZeneca’s Latest Study on AZD2389: What Investors Need to Know
PremiumCompany AnnouncementsAstraZeneca’s Latest Study on AZD2389: What Investors Need to Know
15d ago
AZN
PRXL
AstraZeneca’s New Ovarian Cancer Study: What Investors Need to Know
Premium
Company Announcements
AstraZeneca’s New Ovarian Cancer Study: What Investors Need to Know
15d ago
AZN
PRXL
AstraZeneca’s Tozorakimab Study: A New Frontier in Drug Delivery
Premium
Company Announcements
AstraZeneca’s Tozorakimab Study: A New Frontier in Drug Delivery
16d ago
AZN
PRXL

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >